Actively Recruiting
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Led by University of Colorado, Denver · Updated on 2025-09-30
38
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
A
American Heart Association
Collaborating Sponsor
AI-Summary
What this Trial Is About
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the acute effect (1-hour, 2-hours, and 3-hours post ingestion) of oral equol supplementation on vascular function in postmenopausal women with and without CKD.
CONDITIONS
Official Title
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Postmenopausal women aged 50 to 69 years
- Women with stage 3-4 CKD (eGFR 15-59 ml/min/1.73m2) as determined by CKD-EPI 2021 equation
- Women without CKD (eGFR >60 ml/min/1.73m2) who are healthy without hypertension, kidney disease, cardiovascular disease, diabetes, or other chronic diseases
You will not qualify if you...
- Use of hormone replacement therapy currently or within 6 months prior to enrollment
- Advanced CKD requiring dialysis
- History of kidney transplant
- Use of immunosuppressant medications unless on stable dosage for quiescent disease
- Current or recent (last 12 months) tobacco or nicotine use
- Use of antioxidants or omega-3 supplements within 2 weeks prior to testing
- Marijuana use within 2 weeks prior to testing
- Consumption of soy or soy-based products within 3 days prior to testing
- Uncontrolled hypertension in CKD group (blood pressure >140/90 mmHg)
- Atrial fibrillation
- Active infection or receiving antibiotic therapy
- Hospitalization within the last month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
E
Ester Oh
CONTACT
E
Emily Andrews
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here